The renoprotective effect of antihypertensive drugs.

Abstract

Some antihypertensive drugs may have a renoprotective effect, that is partially independent of their ability to reduce blood pressure. ACE-inhibitors are safe and effective agents that are capable of reducing proteinuria and preventing CRF progression. The results of the AIPRI extension study suggest that they may also have a long-term renoprotective effect. ACE gene polymorphism may partially influence the response to these agents. Angiotensin II receptor 1 antagonists (AT1RA) are effective in reducing proteinuria, but their clinical impact is still a matter of study. It has been shown that non-dihydropyridine and some dihydropyridine calcium channel blockers (CCBs) reduce proteinuria and are also renoprotective, but there is a lack of large-scale prospective randomised trials. Given that the use of various drugs is usually needed to achieve good blood pressure control in patients with CRF, the possibility that a combination of ACE-inhibitors with CCBs or ATIRAs may have an additive renoprotective effect is intriguing.

• Authors: F Locatelli, L Del Vecchio, P Marai, S Colzani
• Journal: Journal of nephrology (J Nephrol) 1998 Nov-Dec Vol. 11 Issue 6 Pg. 330-6 ISSN: 1121-8428 [Print] Italy
• PMID: 10048500 (Publication Type: Journal Article, Review)

Chemical References

• Angiotensin Receptor Antagonists
• Angiotensin-Converting Enzyme Inhibitors
• Antihypertensive Agents
• Calcium Channel Blockers
• Angiotensin II

Topics

• Angiotensin II (physiology)
• Angiotensin Receptor Antagonists
• Angiotensin-Converting Enzyme Inhibitors (administration & dosage, therapeutic use)
• Antihypertensive Agents (therapeutic use)
• Calcium Channel Blockers (administration & dosage, therapeutic use)
• Drug Therapy, Combination
• Humans
• Kidney (drug effects)